CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
with either gemcitabine plus nab-paclitaxel (G/NP) or FOLFIRINOX in the treatment of participants with locally advanced, unresectable pancreatic...
Phase 3
Columbus, Ohio, United States and 89 other locations
A phase IIb, open-label, randomized study of Nab-Paclitaxel and Gemcitabine and plus/minus VCN-01 in Patients with Metastatic Pancreatic Cancer...
Phase 2
Columbus, Ohio, United States and 16 other locations
open label, multi-center, clinical study of Chimeric Antigen Receptor T Cells (CAR-T) targeting claudin18.2 in patients with advanced gastric, pancreatic...
Phase 1, Phase 2
Columbus, Ohio, United States and 15 other locations
A Phase 1/1b dose finding study to determine the OBD(s) and RP2D(s) of BMF-219, a covalent menin inhibitor small molecule, in subjects with KRAS muta...
Phase 1
Columbus, Ohio, United States and 22 other locations
or without SBP-101 in subjects previously untreated for metastatic pancreatic ductal adenocarcinoma (PDA), including subjects who have recei...
Phase 2, Phase 3
Columbus, Ohio, United States and 91 other locations
This is a Phase 2, multicenter, open-label, 3-arm, randomized, parallel group study to evaluate the efficacy and safety of TTX-030 with or without bu...
Phase 2
Columbus, Ohio, United States and 45 other locations
The purpose of this study is to further evaluate the efficacy and safety of niraparib in patients with locally advanced or metastatic solid tumors an...
Phase 2
Columbus, Ohio, United States and 79 other locations
This is a single arm phase II study. All patients will receive 3 cycles of the treatment of nab-paclitaxel (Days 1, 8 and 15), gemcitabine (Days 1, 8...
Phase 2
Columbus, Ohio, United States
The purpose of this study is to find out whether the study drug, LY4170156, is safe, tolerable and effective in participants with advanced solid tumo...
Phase 1
Columbus, Ohio, United States and 3 other locations
This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor...
Phase 2
Columbus, Ohio, United States and 122 other locations
Clinical trials
Research sites
Resources
Legal